Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
Islamic State group militants claim capture and execution of a Nigerian brigadier general- Vagus nerve stimulation shows promise as a way to counter Alzheimer’s disease- and age-related memory loss
- Oldest evidence of human fire-making discovered at site in England
- Instructions to Upgrade the Proficiency of Your Sunlight powered chargers
- ‘RichTok’ Influencer Becca Bloom Shows Off Custom Invitations and ‘Most Valued Possession’ from Her Viral 2025 Wedding
- When darkness shines: How dark stars could illuminate the early universe
- Ariana Grande and Jonathan Bailey will reunite for 'Sunday in the Park With George'
- This cafe takes orders in sign language. It's cherished by the Deaf community
- What's the new 'Knives Out' mystery about? Everything to know about 'Wake Up Dead Man,' including who's in the cast and what the reviews say.
